RECRUITING

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Talk to us

Conditions

Prurigo Nodularis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.

Official Title

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Quick Facts

Study Start:2025-08-11
Study Completion:2027-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06988618

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
  2. * Participants greater than or equal to (\>=) 18 years of age.
  3. * Participants who signed the written informed consent form (ICF).
  1. * Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;
  2. * Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline.
  3. * Participants who received nemolizumab previously.
  4. * Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Contacts and Locations

Study Contact

Galderma Research and Development
CONTACT
817-961-5000
clinical.studies@galderma.com

Study Locations (Sites)

Galderma Investigational Site # 8893
Birmingham, Alabama, 35244
United States
Galderma Investigational Site # 7077
Phoenix, Arizona, 85006-2754
United States
Galderma Investigational Site # 7060
Phoenix, Arizona, 85008-3884
United States
Galderma Investigational Site # 7067
Tucson, Arizona, 85718
United States
Galderma Investigational Site # 7074
Corona, California, 92882
United States
Galderma Investigational Site # 6836
Fountain Valley, California, 92708-3701
United States
Galderma Investigational Site # 8224
Fremont, California, 94538-1603
United States
Galderma Investigational Site # 7064
Santa Monica, California, 90404-2216
United States
Galderma Investigational Site # 7061
Castle Rock, Colorado, 80109-8034
United States
Galderma Investigational Site # 7059
Fairfield, Connecticut, 06824
United States
Galderma Investigational Site # 7087
Coral Gables, Florida, 33134
United States
Galderma Investigational Site # 7063
Cutler Bay, Florida, 33157
United States
Galderma Investigational Site # 7078
Miami, Florida, 33173
United States
Galderma Investigational Site # 7070
North Miami Beach, Florida, 33162-4708
United States
Galderma Investigational Site # 7091
Tampa, Florida, 33615-4537
United States
Galderma Investigational Site # 7058
Chicago, Illinois, 60641
United States
Galderma Investigational Site # 8142
Indianapolis, Indiana, 46250-2041
United States
Galderma Investigational Site # 8012
Glendale, Maryland, 20769-9182
United States
Galderma Investigational Site # 7068
Rockville, Maryland, 20850-6243
United States
Galderma Investigational Site # 7065
Brighton, Massachusetts, 02135
United States
Galderma Investigational Site # 7066
Auburn Hills, Michigan, 48326-3396
United States
Galderma Investigational Site # 7071
Caledonia, Michigan, 49316-7478
United States
Galderma Investigational Site # 7072
Troy, Michigan, 48084-5260
United States
Galderma Investigational Site # 7053
Waterford, Michigan, 48328
United States
Galderma Investigational Site # 7057
Lee's Summit, Missouri, 64064
United States
Galderma Investigational Site # 7076
Saint Louis, Missouri, 63141-7068
United States
Galderma Investigational Site # 7055
Portsmouth, New Hampshire, 03801-7156
United States
Galderma Investigational Site # 7080
Auburn, New York, 13021
United States
Galderma Investigational Site # 7052
East Syracuse, New York, 13057
United States
Galderma Investigational Site # 8282
Mount Kisco, New York, 10549-3035
United States
Galderma Investigational Site # 7056
New York, New York, 10012-1354
United States
Galderma Investigational Site # 7051
New York, New York, 10023
United States
Galderma Investigational Site # 7081
Dayton, Ohio, 45414-2799
United States
Galderma Investigational Site # 8559
Philadelphia, Pennsylvania, 19103-4738
United States
Galderma Investigational Site # 8238
Dallas, Texas, 75230-5808
United States
Galderma Investigational Site # 7062
Edinburg, Texas, 78539-4660
United States
Galderma Investigational Site # 7088
Grapevine, Texas, 76051
United States
Galderma Investigational Site # 7069
Sugar Land, Texas, 77478-3842
United States
Galderma Investigational Site # 7079
Vienna, Virginia, 22182
United States

Collaborators and Investigators

Sponsor: Galderma R&D

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-11
Study Completion Date2027-11-30

Study Record Updates

Study Start Date2025-08-11
Study Completion Date2027-11-30

Terms related to this study

Additional Relevant MeSH Terms

  • Prurigo Nodularis